[Asia Economy Reporter Myunghwan Lee] SD Biosensor announced on the 7th that it participated in 'MEDLAB Middle East 2023' held in Dubai, United Arab Emirates.
MEDLAB 2023, the world's largest diagnostic and medical device exhibition celebrating its 7th edition this year, is being held for four days from the 6th to the 9th of this month at the Dubai World Trade Center in the United Arab Emirates.
SD Biosensor showcased its rapid molecular diagnostic platform 'Standard M10,' which is supplied to European and Asian countries.
They attracted significant attention by exhibiting a total of eight cartridges with CE approval for respiratory, tuberculosis, sexually transmitted diseases, and gastrointestinal infections: ▲Flu/RSV/SARS-CoV-2 (simultaneous diagnosis of flu and COVID-19) ▲MDR-TB (drug-resistant tuberculosis test) ▲MTB/NTM (tuberculosis test) ▲HPV (human papillomavirus test) ▲Arbovirus Panel (arbovirus test) ▲C.difficile (colon test) ▲SARS-CoV-2 (COVID-19 test) ▲SARS-CoV-2 Turbo (COVID-19 LAMP test). Additionally, they introduced for the first time the fluorescent immunoassay Mycoplasma (STANDARD F M.pneumoniae) antigen and antibody product, which is scheduled for official release.
Kim Yongjin, Head of Overseas Sales at SD Biosensor, said, “The Middle East region has been a proactive market where SD Biosensor has established a strong presence with exclusive dealers since the company's early days. We were able to reaffirm the high interest in respiratory diagnostic products such as flu, respiratory syncytial virus, and adenovirus, as well as the excellence of related products.” He added, “We will strengthen our growth momentum and solidify our position in the global market with our flagship product M10 and the fluorescent immunoassay brand 'Standard F.'”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
